Claims
- 1. A method of treating ulcers with lansoprazole which comprises administering to a human a therapeutically effective amount of optically pure R(+) isomer of lansoprazole, or a pharmaceutically acceptable salt thereof.
- 2. A method of treating gastroesophageal reflux disease which comprises administering to a human a therapeutically effective amount of optically pure R(+) isomer of lansoprazole, or a pharmaceutically acceptable salt thereof.
- 3. A method of treating a condition caused by or contributed to by gastric hypersecretion which comprises administering to a human a therapeutically effective amount of optically pure R(+) isomer of lansoprazole, or a pharmaceutically acceptable salt thereof.
- 4. The method according to claim 3 wherein said condition is Zollinger-Ellison Syndrome.
- 5. A method of treating psoriasis which comprises administering to a human a therapeutically effective amount of optically pure R(+) isomer of lansoprazole, or a pharmaceutically acceptable salt thereof.
- 6. The method of any of claims 1-5 wherein (+) lansoprazole is administered orally.
- 7. The method of claim 6 wherein the amount of (+) lansoprazole or a pharmaceutically acceptable salt thereof administered is from about 5 mg to about 180 mg per day.
- 8. The method of claim 7 wherein the amount administered is from about 10 mg to about 60 mg per day.
- 9. The method of any of claims 1-5 wherein the amount of (+) lansoprazole or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total weight of lansoprazole.
- 10. The method of any of claims 1-5 wherein the amount of (+) lansoprazole or a pharmaceutically acceptable salt thereof is greater than approximately 99% by weight of the total weight of lansoprazole.
- 11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier for oral therapy and a therapeutically effective amount of (+) lansoprazole or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.
- 12. A pharmaceutical composition according to claim 11 in the form of a tablet or capsule.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority of U.S. provisional application 60/073,140, filed Jan. 30, 1998, the disclosure of which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60073140 |
Jan 1998 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09721086 |
Nov 2000 |
US |
Child |
09981108 |
Oct 2001 |
US |
Parent |
09240973 |
Jan 1999 |
US |
Child |
09721086 |
Nov 2000 |
US |